Find a Doctor or Practice Location

You can also search for providers and practices at Penn Medicine Lancaster General Health or Princeton Health.

I am searching for a
Reset Form
Peter J. O'Dwyer, MD

Peter J. O'Dwyer, MD Physician

Director, Developmental Therapeutics Program, Abramson Cancer Center Assistant Professor of Clinical Pathology and Laboratory Medicine

Dr. O'Dwyer is employed by Penn Medicine.

About Dr. Peter J. O'Dwyer

Recognized by Best Doctors in America 2003 - 2018

Patient Satisfaction Ratings

Patient Rating Breakdown

The Patient Satisfaction Rating is an average of all responses to the care provider related questions shown below from our nationally-recognized Press Ganey Patient Satisfaction Survey. Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.

Responses are measured on a scale of 1 to 5 with 5 being the best score.

Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.

Overall Ratings

Clinical Specialties


  • Medical Oncology

Programs & Centers:

Board Certification:

  • Internal Medicine, 1981
  • Medical Oncology, 1987
  • Pediatrics, 1983

Clinical Expertise:

  • Abdominal Chemotherapy
  • Anal Cancer
  • Anorectal Cancer
  • Appendix Cancer
  • Bile Duct Cancer (Cholangiocarcinoma)
  • Biological Targeted Therapy
  • Cancer Chemotherapy
  • Carcinoid of the Stomach
  • Carcinoid Tumor of Pancreas
  • Carcinoid Tumors
  • Colon Cancer Chemotherapy
  • Colorectal Cancer
  • Cystadenoma of Pancreas
  • Esophageal Cancer
  • Esophagogastric Junction Cancer
  • Gallbladder Cancer
  • Gallbladder Mass
  • Gastrointestinal Stromal Tumors (GIST)
  • Hepatobiliary Malignancies
  • Hereditary Colon Cancer
  • Hereditary Nonpolyposis Colorectal Cancer
  • Immunotherapy
  • Insulinoma
  • Liver Cancer
  • Malignant Neoplasm of Pancreatic Duct
  • Malignant Tumor of Extrahepatic Bile Duct
  • Neuroendocrine Tumors
  • Pancreatic Neuroendocrine Tumors (Islet Cell Tumors)
  • Pseudomyxoma Peritonei
  • Rectal Cancer
  • Small Bowel Cancer
  • Small Intestine Cancer
  • Squamous Cell Carcinoma of the Esophagus
  • Stomach Cancer (Gastric Cancer)
Show All Expertise

Practice Locations and Appointments

Insurance Accepted

  • Aetna US Healthcare
  • Amerihealth Caritas
  • Amerihealth Caritas Medicare
  • Cigna
  • Cigna HealthSpring
  • Clover Health Plan
  • CVS Health
  • Devon Health Services (Americare)
  • eLAP Services
  • Gateway Health Plan
  • Geisinger Health Plan
  • HealthAmerica / HealthAssurance, a Coventry Plan
  • HealthPartners
  • HealthPartners Medicare
  • HealthSmart
  • Highmark Blue Shield
  • Homestead Smart Health Plans
  • Horizon Blue Cross Blue Shield of New Jersey
  • Humana / Choicecare
  • Independence Blue Cross (Keystone East)
  • Intergroup
  • Keystone First
  • Keystone First Medicare
  • Multiplan
  • NJ Medicaid
  • NJ Qualcare
  • Oscar Health Plan of PA
  • Oxford Health Plan
  • PA Health and Wellness (Centene) Medicare
  • PA Medicaid
  • PA Medicare
  • Preferred Health Care/LGH
  • Provider Partners Health Plan
  • Rail Road Medicare / Palmetto GBA
  • Remedy Partners at Penn Medicine
  • Tricare
  • United Healthcare
  • UnitedHealthcare Community Plan
  • US Family Health Plan
  • Veterans Choice Program

Education and Training

Medical School: University of Dublin Trinity College
Residency: Saint Patrick's Hospital and Health Sciences Center
Residency: Hammersmith Hospital
Residency: The Waterbury Hospital Health Center
Residency: Greater Baltimore Medical Center
Fellowship: University of Maryland Hospital
Fellowship: National Cancer Institute


11th NCI/EORTC/AACR Symposium on New Drugs in Cancer Therapy, 2nd International Workshop on Targeted Therapy in Colorectal Cancer, 3rd International Pharmacodynamics Workshop, Tidewater, Virginia, 7th International Meeting on Chemical Modifiers of Cancer Treatment, Adjuvant Colon Studies, NSABP, American Association for Cancer Research, American Association for the Advancement of Science, American Cancer Society, American College of Physicians, American Federation Clinical Research, American Society of Clinical Oncology, American Society of Clinical Pharmacology and Therapeutics, American Society of Hematology, American Society of Preventive Oncology, Center for Biomedical Continuing Education, Center for Biomedical Continuing Education, College of Physicians Philadelphia, Colon Cancer Alliance, Eastern Cooperative Oncology Group, EORTC 1st Translational Research Symposium, Brussels, EORTC Protocol Review Committee, Festschrift for Dr. Patrick Creaven, Buffalo, Gastrointestinal Cancer, International Congress of Chemotherapy, International Meta-Analysis Group in Cancer, International Workshop on Targeted Therapy in Colorectal Cancer, National Cancer Institute, New Agents/Pharmacology, CALGB, Pennsylvania Oncology Society, Pharmacokinetics and Metabolism Group, EORTC, SPORE in pancreatic cancer, NYU, Summit on Clinical Trials, Washington, DC, Summit V, Workgroup on Trial Design, U.S.-Japan Cancer Research Symposium, Tokyo, Working Group on ECOG/EORTC Coordination,

Hospital Affiliation

Dr. O'Dwyer is employed by Penn Medicine.

Hospital Privileges:

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
  • Penn Presbyterian Medical Center: Has privileges to treat patients in the hospital.


Selected Publications:

Shirao K, Hoff PM, Ohtsu A, Loehrer PJ, Hyodo I, Wadler S, Wadleigh RG, O’Dwyer PJ, Muro K, Yamada Y, Boku N, Nagashima F, Abbruzzese JL: Comparison between the efficacy, toxicity, and pharmacokinetics of a uracil/tegafur plus oral leucovorin regimen in Japanese and American patients with advanced colorectal cancer: joint USA and Japan study of UFT/LV : 2003.

Flaherty KT, Stevenson JP, Hahn SM, Redlinger M, O’Dwyer PJ: Dose escalation and safety study of gemcitabine, carboplatin, and paclitaxel in patients with adavanced malignancy Cancer Chemother Pharmacol : 2003.

Giantonio BJ, Derry C, McAleer C, McPhillips JJ, O’Dwyer PJ: Phase I and pharmacokinetic study of the cytotoxic ether lipid ilmofosine administered by weekly 2-hour infusion in patients with advanced solid tumors : 2003.

Yao KS, O’Dwyer PJ: Role of the AP-1 element in mediating transcriptional induction of DT-diaphorase gene expression by oltipraz: a target for chemoprevention Biochem Pharmacol : 2003.

Schaner ME, Ross DT, Ciaravino G, Sorlie T, Troyanskaya O, Diehn M, Wang YC, Duran GE, Sikic TL, Caldeira S, Skomedal H, Tu I-P, Hernandez-Boussard T, Johnson SW, O’Dwyer PJ, Fero M, Kristensen GB, Borresen-Dale A-L, Hastie T, Tibshirani R, van de Rijn M, Teng NN, Longacre TA, Botstein D, Brown PO, Sikic BI: Gene expression patterns in epithelial ovarian carcinomas : 2003.

Flaherty KT, O'Dwyer PJ: Phase II trials in oncology Anticancer Drug Development Guide : 2003.

Vasilevskaya I, O’Dwyer PJ: Role of Jun and Jun kinase (JNK) in resistance of cancer cells to therapy Drug Resistance Updates : 2003.

O’Dwyer PJ, Johnson SW: Current status of oxaliplatin in colorectal cancer Semin Oncol 30 (3 Supp 6): 78-87,2003.

Bilenker JH, Stevenson JP, Flaherty KT, Algazy K, McLaughlin K, Haller DG, Giantonio BJ, Garcia-Vargas JE, O’Dwyer PJ: Phase I trial of the antifolate ZD9331 in combination with cisplatin in patients with refractory solid malignancies : 2003.

Veronese ML, Stevenson JP, Sun W, Redlinger M, Algazy K, Giantonio BJ, Hahn S, Vaughn D, Haller DG, O’Dwyer PJ: Phase I trial of UFT/leucovorin and irinotecan in patients with advanced cancer : 2003.

Academic Contact Info

Division of Hematology Oncology
Perelman Center for Advanced Medicine
10th Floor, South Pavilion
Office #10-301
3400 Civic Center Blvd

Philadelphia, PA 19104
Phone: (215) 662-7606
Patient appointments: 800-789-7366

Related Links